Browse grants
Federal and state grant opportunities with plain-English eligibility summaries. We aggregate public records — always verify the details on the funder’s site before applying. Or browse the complete index →
Priority HIV/AIDS Research within the Mission of NIDDK (R01 Clinical Trial Optional)
Due Nov 5, 2027National Institutes of Health · Amount varies
This NIH/NIDDK R01 funds HIV/AIDS research aligned with NIDDK's mission and the NIH Office of AIDS Research priorities. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations rather than individuals. No award amount is specified. Projects must fit the stated HIV/AIDS research priorities, so the scope is specific.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreLimited Competition: Renewal of Existing NINDS-Supported Clinical Trial Cooperative Agreement Awards (U01 - Clinical Trials Required)
Due Nov 5, 2027National Institutes of Health · Amount varies
This NIH/NINDS U01 is a limited competition open only to applicants holding existing NINDS-supported clinical trial cooperative agreement awards that need more time and resources to finish. Because it is restricted to current grantees, new applicants are not eligible; foreign organizations are also excluded. No award amount is specified. This opportunity does not apply to organizations that do not already hold the relevant NINDS award.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreAlzheimer's Drug-Development Program (U01 Clinical Trial Optional)
Due Nov 5, 2027National Institutes of Health · Up to $1.5M
This NIH/NIA U01 funds preclinical and early (Phase I) clinical development of new drug candidates that aim to prevent, slow, or treat Alzheimer's disease. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Awards run up to about $1.5 million. Basic mechanism studies, repurposed drugs, and stand-alone clinical trials are out of scope, so the research focus is narrow.
ResearchersSchools & universitiesGovernment / tribalNonprofits+2 moreBRAIN Initiative: Theories, Models and Methods for Analysis of Complex Data from the Brain (R01 Clinical Trial Not Allowed)
Due Nov 8, 2027National Institutes of Health · Amount varies
This NIH BRAIN Initiative R01 funds development of computational theories, models, and methods for analyzing complex brain-circuit data, to be shared with the research community. Eligible applicants are research organizations, including faith- or community-based organizations, tribal governments, foreign organizations, and U.S. territories; it targets institutions rather than individuals. No award amount is specified. The work is narrowly scoped to neural-circuit tool building, so confirm fit before applying.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreCareer Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Not Allowed)
Due Nov 12, 2027National Institutes of Health · Amount varies
This NIH/NINDS K22 career-transition award helps NINDS intramural neurologist- and neurosurgeon-scientists move to independent academic faculty positions; no clinical trial is allowed. It is applied for through a research or education institution but is restricted to NINDS intramural clinician-scientists, so eligibility is very narrow; foreign organizations and components are not eligible. No award amount is specified. Most outside applicants will not qualify for this opportunity.
ResearchersSchools & universitiesIndividualsNarrow eligibilityCareer Transition Award for NINDS Intramural Clinician-Scientists (K22 Clinical Trial Required)
Due Nov 12, 2027National Institutes of Health · Amount varies
This NIH/NINDS K22 career-transition award helps NINDS intramural neurologist- and neurosurgeon-scientists move to independent academic faculty positions, with a clinical trial required. It is applied for through a research or education institution but is restricted to NINDS intramural clinician-scientists, making eligibility very narrow; foreign organizations and components are not eligible. No award amount is specified. Most outside applicants will not qualify for this opportunity.
ResearchersSchools & universitiesIndividualsNarrow eligibilityNIA Academic Leadership Career Award (K07 Independent Clinical Trial Not Allowed)
Due Nov 12, 2027National Institutes of Health · Amount varies
This NIH/NIA K07 career award supports established investigators who lead efforts to build aging and Alzheimer's/dementia research capacity, mentorship, and infrastructure at their academic institution. It is applied for through a research or education institution but effectively targets individual senior investigators; foreign organizations are not eligible, and it does not allow leading an independent clinical trial. No award amount is specified. Applicants should confirm they meet the leadership and career-stage criteria, which are specific.
ResearchersSchools & universitiesIndividualsNarrow eligibilityNIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)
Due Nov 12, 2027National Institutes of Health · Up to $350K
This NIH/NIDA award funds research education programs that train clinicians and clinical researchers in substance use and substance use disorder research. Eligible applicants are research and education institutions, including HBCUs, Hispanic-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it is aimed at organizations, not individuals. Awards run up to about $350,000. Note the program supports research education only, not non-research clinical training, so review the stated scope carefully.
ResearchersSchools & universitiesGovernment / tribalNonprofits+2 moreToward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
Due Nov 15, 2027National Institutes of Health · Amount varies
This NIH/NCI R01 funds advanced preclinical research translating nanotechnology-based cancer diagnostics and therapeutics toward later NCI translational programs; no clinical trial is allowed. Eligible applicants are research and education institutions, including minority-serving and tribal-serving institutions, faith- or community-based organizations, and tribal governments; it targets research organizations, not individuals. Foreign organizations are not eligible. No award amount is specified, and the nanomedicine focus makes the scope narrow.
ResearchersSchools & universitiesGovernment / tribalNonprofits+1 moreLeveraging Network Infrastructure to Conduct Innovative Research for Women, Children, Pregnant and Lactating Women, and Persons with Disabilities (UG3/UH3 - Clinical Trial Optional)
Due Nov 15, 2027National Institutes of Health · Up to $6.3M
This NIH award lets investigators use NICHD's existing clinical research network infrastructure to run multisite trials and studies on infant, child, women's, and disability health, structured as a start-up phase followed by full enrollment. Applications must be submitted jointly with an NICHD-supported network Data Coordinating Center, which narrows this to investigators already positioned within that network. Awards can reach up to $6,250,000.
ResearchersLarge awardNarrow eligibilityPilot Projects Investigating Understudied Proteins Associated with Rare Diseases (R03 Clinical Trial Not Allowed)
Due Nov 16, 2027National Institutes of Health · Up to $100K
This NIH (R03) opportunity funds pilot projects generating preliminary data on a defined list of understudied proteins associated with rare diseases. It is intended for research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $100,000.
ResearchersSchools & universitiesSmall awardNarrow eligibilityPilot Studies of Biological, Behavioral and Social Mechanisms Contributing to HIV Pathogenesis Within the Mission of NIDDK (R21 Clinical Trial Not Allowed)
Due Nov 16, 2027National Institutes of Health · Amount varies
This NIDDK (R21) opportunity funds basic and translational pilot research on biological, behavioral, and social mechanisms contributing to HIV pathogenesis within NIDDK's mission. It is intended for research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityInnovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R21 - Clinical Trial Optional)
Due Nov 16, 2027National Institutes of Health · Up to $200K
This NIH (R21) opportunity funds research developing novel screening approaches or therapies for fatal or disabling conditions identified through newborn screening, including high-priority genetic conditions. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. The maximum award is about $200,000.
ResearchersSchools & universitiesNarrow eligibilityInnovative Screening Approaches and Therapies for Screenable Disorders in Newborns (R01 - Clinical Trial Optional)
Due Nov 16, 2027National Institutes of Health · Amount varies
This NIH (R01) opportunity funds research developing novel screening approaches or therapies for fatal or disabling conditions identified through newborn screening, including high-priority genetic conditions. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityBasic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)
Due Nov 16, 2027National Institutes of Health · Amount varies
This NIH (R21) opportunity funds basic, mechanistic research into the biological and genetic causes of cancer health disparities, including new methods, models, and secondary data analyses. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityChemical Countermeasures Research Program (CCRP) Initiative: Basic Research on The Deleterious Effects of Acute Exposure to Ultra-Potent Synthetic (UPS) Opioids (R01 Clinical Trial Not Allowed)
Due Nov 18, 2027National Institutes of Health · Up to $300K
This NIH (R01) opportunity funds basic research into the harmful effects of acute exposure to ultra-potent synthetic opioids (e.g., fentanyl, carfentanil, nitazenes) and their combinations, including delayed effects. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. The maximum award is about $300,000.
ResearchersSchools & universitiesNarrow eligibilityDEVCOM ARMY RESEARCH LABORATORY BROAD AGENCY ANNOUNCEMENT FOR FOUNDATIONAL RESEARCH
Due Nov 20, 2027Dept of the Army -- Materiel Command · Amount varies
This U.S. Army Research Laboratory Broad Agency Announcement solicits foundational (basic and applied) research proposals supporting Army modernization. Eligibility is broad, including universities, nonprofits, state and local governments, foreign organizations, and for-profit firms (large and small businesses). It uses a competitive merit-based process; no specific award amount is stated.
ResearchersNonprofitsSmall businessSchools & universities+2 moreAccelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
Due Dec 3, 2027National Institutes of Health · Amount varies
This NIH (R01) opportunity funds innovative analysis of existing social, behavioral, administrative, and neuroimaging datasets to study substance-use behaviors, related disorders, prevention, and health-service use. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityAccelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
Due Dec 3, 2027National Institutes of Health · Amount varies
This NIH (R21) opportunity funds innovative analysis of existing social, behavioral, administrative, and neuroimaging datasets to study substance-use behaviors, related disorders, prevention, and health-service use. It is intended for research and academic institutions rather than individuals or general nonprofits/small businesses. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibilityCatalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
Due Dec 23, 2027National Institutes of Health · Amount varies
This NHLBI Catalyze (R61/R33) phased opportunity funds medical device prototype design and testing, disease-target identification, and assay development for heart, lung, blood, and sleep diseases. It is aimed at research and academic institutions; foreign organizations are not eligible to apply. No specific award amount is stated.
ResearchersSchools & universitiesNarrow eligibility